ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

Malcolm Ranson; Lisa A Hammond; David Ferry; Mark Kris; Andrew Tullo; Philip I Murray; Vince Miller; Steve Averbuch; Judy Ochs; Charles Morris; Andrea Feyereislova; Helen Swaisland; Eric K Rowinsky

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

Malcolm Ranson, Lisa A Hammond, David Ferry, Mark Kris, Andrew Tullo, Philip I Murray, Vince Miller, Steve Averbuch, Judy Ochs, Charles Morris, Andrea Feyereislova, Helen Swaisland, Eric K Rowinsky

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

729 Citations (Scopus)

Abstract

To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors.

Original language	English
Pages (from-to)	2240-50
Number of pages	11
Journal	Journal of Clinical Oncology
Volume	20
Issue number	9
Publication status	Published - 2002

Cite this

Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., Feyereislova, A., Swaisland, H., & Rowinsky, E. K. (2002). ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. Journal of Clinical Oncology, 20(9), 2240-50.

@article{2748872dc13b4eea8a665877941768eb,

title = "ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial",

abstract = "To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors.",

author = "Malcolm Ranson and Hammond, {Lisa A} and David Ferry and Mark Kris and Andrew Tullo and Murray, {Philip I} and Vince Miller and Steve Averbuch and Judy Ochs and Charles Morris and Andrea Feyereislova and Helen Swaisland and Rowinsky, {Eric K}",

year = "2002",

language = "English",

volume = "20",

pages = "2240--50",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "9",

}

Ranson, M, Hammond, LA, Ferry, D, Kris, M, Tullo, A, Murray, PI, Miller, V, Averbuch, S, Ochs, J, Morris, C, Feyereislova, A, Swaisland, H & Rowinsky, EK 2002, 'ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial', Journal of Clinical Oncology, vol. 20, no. 9, pp. 2240-50.

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. / Ranson, Malcolm; Hammond, Lisa A; Ferry, David et al.
In: Journal of Clinical Oncology, Vol. 20, No. 9, 2002, p. 2240-50.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors

T2 - results of a phase I trial

AU - Ranson, Malcolm

AU - Hammond, Lisa A

AU - Ferry, David

AU - Kris, Mark

AU - Tullo, Andrew

AU - Murray, Philip I

AU - Miller, Vince

AU - Averbuch, Steve

AU - Ochs, Judy

AU - Morris, Charles

AU - Feyereislova, Andrea

AU - Swaisland, Helen

AU - Rowinsky, Eric K

PY - 2002

Y1 - 2002

N2 - To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors.

AB - To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors.

M3 - Article

C2 - 11980995

SN - 0732-183X

VL - 20

SP - 2240

EP - 2250

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 9

ER -

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

Abstract

Fingerprint

Cite this